Synopsis
Synopsis
0
VMF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
2. 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1h-benzimidazole
3. Aciphex
4. Dexrabeprazole
5. E 3810
6. E3810
7. Ly 307640
8. Ly-307640
9. Ly307640
10. Pariet
11. Rabeprazole
12. Sodium, Rabeprazole
1. 117976-90-6
2. Rebeprazole Sodium
3. Pariet
4. Aciphex
5. Rabeprazole Sodium Salt
6. Dexrabeprazole Sodium
7. Rabeprazole (sodium)
8. (s)-rabeprazole Sodium Salt
9. Aciphex Sprinkle
10. Ly307640 Sodium
11. Sodium Rabeprazole
12. Rabeprazole Sodium [usan]
13. Idiazole
14. Rabeprazole Na
15. Chebi:8769
16. 171440-19-0
17. Ly-307640
18. E3810
19. E-3810 Sodium
20. Sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide
21. Ly-307640 Sodium
22. 3l36p16u4r
23. 1h-benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, Sodium Salt
24. 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridyl)methyl)sulfinyl)benzimidazole Sodium Salt
25. Nsc-759270
26. Dsstox_cid_24205
27. Dsstox_rid_80118
28. Dsstox_gsid_44205
29. 1h-benzimidazole, 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-, Sodium Salt (1:1)
30. Rabicip
31. Pepcia
32. Aciphex Sodium
33. Ly 307640 Sodium
34. Habeprazole Sodium
35. Sodium 2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)benzo[d]imidazol-1-ide
36. Sodium 2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazol-1-ide
37. Smr000550493
38. Cas-117976-90-6
39. Ncgc00159518-02
40. E 3810
41. Pariete
42. Unii-3l36p16u4r
43. Pariprazole Sodium
44. Dexrabeprazolesodium
45. Rebeprazole Sodium;
46. Aciphex (tn)
47. Pariet (tn)
48. Rebeprazole Sodium Salt
49. Rabeprazole Sodium- Bio-x
50. Mls001165734
51. Mls006010621
52. Schembl140494
53. Rabeprazole Na [vandf]
54. Chembl1200930
55. Dtxsid3044205
56. Rabeprazole Sodium [jan]
57. Hy-b0656a
58. Rabeprazole Sodium (jp17/usp)
59. Ex-a176
60. Hms2093h10
61. Hms2231e04
62. Hms3373b05
63. Rabeprazole Sodium [mart.]
64. Bcp06639
65. Rabeprazole Sodium [usp-rs]
66. Rabeprazole Sodium [who-dd]
67. Tox21_111736
68. Tox21_302317
69. Ac-715
70. Bdbm50247881
71. Mfcd02092688
72. Rabeprazole Sodium Salt [mi]
73. S4665
74. Rabeprazole Sodium, >=98% (hplc)
75. Akos015895734
76. Akos015962116
77. Akos025310160
78. Tox21_111736_1
79. Am81231
80. Ccg-213574
81. Ccg-268423
82. Nsc 759270
83. Rabeprazole Sodium [orange Book]
84. Ncgc00159518-05
85. Ncgc00255838-01
86. Rabeprazole Sodium [ep Monograph]
87. As-13338
88. Br167318
89. Rabeprazole Sodium [usp Monograph]
90. Ft-0631090
91. Ft-0689461
92. R0115
93. C07865
94. D00724
95. F17418
96. 976r906
97. Sr-01000799133
98. J-010726
99. Q-201655
100. Sr-01000799133-2
101. Q27108142
102. [2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridyl]methylsulfinyl]benzimidazol-1-yl]sodium
103. Sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1h-benzimidazole
104. 1h-benzimidazole,2-[[[4-(3-methoxypropoxy)- 3-methyl-2-pyridinyl]methyl]sulfinyl]-,sodium Salt
105. 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole, Sodium Salt
106. Sodium 2-(((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methyl)sulfinyl)benzo[d]imidazol-1-ide
Molecular Weight | 381.4 g/mol |
---|---|
Molecular Formula | C18H20N3NaO3S |
Hydrogen Bond Donor Count | 0 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 8 |
Exact Mass | 381.11230696 g/mol |
Monoisotopic Mass | 381.11230696 g/mol |
Topological Polar Surface Area | 81.5 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 446 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Aciphex |
PubMed Health | Rabeprazole (By mouth) |
Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
Active Ingredient | Rabeprazole sodium |
Dosage Form | Tablet, delayed release |
Route | oral; Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Eisai; Eisai Medcl Res |
2 of 4 | |
---|---|
Drug Name | Rabeprazole sodium |
Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
Active Ingredient | Rabeprazole sodium |
Dosage Form | Tablet, delayed release |
Route | Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Mylan Pharms; Kremers Urban Dev; Teva Pharms Usa; Torrent Pharms; Lupin; Dr Reddys Labs |
3 of 4 | |
---|---|
Drug Name | Aciphex |
PubMed Health | Rabeprazole (By mouth) |
Drug Classes | Antiulcer, Gastric Acid Secretion Inhibitor |
Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
Active Ingredient | Rabeprazole sodium |
Dosage Form | Tablet, delayed release |
Route | oral; Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Eisai; Eisai Medcl Res |
4 of 4 | |
---|---|
Drug Name | Rabeprazole sodium |
Drug Label | The active ingredient in ACIPHEX Delayed-Release Tablets is rabeprazole sodium, a substituted benzimidazole that inhibits gastric acid secretion. Rabeprazole sodium is known chemically as 2-[[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]-methyl]sulfiny... |
Active Ingredient | Rabeprazole sodium |
Dosage Form | Tablet, delayed release |
Route | Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Mylan Pharms; Kremers Urban Dev; Teva Pharms Usa; Torrent Pharms; Lupin; Dr Reddys Labs |
Treatment of duodenal ulcer, Treatment of gastric ulcer, Treatment of gastro-oesophageal reflux disease, Treatment of Helicobacter pylori in patients with peptic ulcer disease, Treatment of Zollinger-Ellison syndrome
Anti-Ulcer Agents
Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief. (See all compounds classified as Anti-Ulcer Agents.)
Proton Pump Inhibitors
Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX. (See all compounds classified as Proton Pump Inhibitors.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.
Date of Issue : 2022-02-22
Valid Till : 2025-07-15
Written Confirmation Number : TFDA-0002291
Address of the Firm :
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
GDUFA
DMF Review : Reviewed
Rev. Date : 2023-08-17
Pay. Date : 2023-07-17
DMF Number : 35344
Submission : 2020-11-27
Status : Active
Type : II
Certificate Number : CEP 2020-387 - Rev 01
Issue Date : 2024-06-21
Type : Chemical
Substance Number : 2331
Status : Valid
Registration Number : 221MF10282
Registrant's Address : Flat No. 302, Bhanu Enclave, Sunder Nagar, Erragadda, Hyderabad-500038, Telangana, India
Initial Date of Registration : 2009-12-22
Latest Date of Registration :
Date of Issue : 2024-04-23
Valid Till : 2027-01-21
Written Confirmation Number : WC-0493
Address of the Firm :
NDC Package Code : 42765-053
Start Marketing Date : 2023-01-24
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (25kg/25kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Leaders Bio Co., Ltd.
Registration Date : 2023-01-19
Registration Number : 20190910-209-J-241(2)
Manufacturer Name : Metrochem API Private Limited (Unit-I)
Manufacturer Address : Plot No. 62/C/6, Pipeline Road, Phase - I, IDA., Jeedimetla, Quthbullapur Mandal Medchal District - 500 055 Telangana, India
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Certificate Number : R0-CEP 2021-023 - Rev 00
Issue Date : 2023-01-10
Type : Chemical
Substance Number : 2868
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 24924
Submission : 2011-05-02
Status : Active
Type : II
Certificate Number : R1-CEP 2017-014 - Rev 00
Issue Date : 2023-04-27
Type : Chemical
Substance Number : 2331
Status : Valid
Available Reg Filing : ASMF |
NDC Package Code : 58032-1023
Start Marketing Date : 2018-10-25
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Rabeprazole Sodium Hydrate, Y-Form
Certificate Number : CEP 2022-468 - Rev 01
Status : Valid
Issue Date : 2024-06-24
Type : Chemical
Substance Number : 2331
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Rabeprazole Sodium Hydrate, RBL Process
Certificate Number : CEP 2022-429 - Rev 01
Status : Valid
Issue Date : 2024-06-21
Type : Chemical
Substance Number : 2331
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Certificate Number : CEP 2020-387 - Rev 01
Status : Valid
Issue Date : 2024-06-21
Type : Chemical
Substance Number : 2331
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Rabeprazole Sodium Hydrate, Form-Y
Certificate Number : R1-CEP 2016-210 - Rev 00
Status : Valid
Issue Date : 2023-04-25
Type : Chemical
Substance Number : 2331
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Certificate Number : R0-CEP 2021-023 - Rev 00
Status : Valid
Issue Date : 2023-01-10
Type : Chemical
Substance Number : 2868
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Rabeprazole Sodium Hydrate, Form-Y (RBL Process)
Certificate Number : R0-CEP 2020-382 - Rev 00
Status : Valid
Issue Date : 2021-03-19
Type : Chemical
Substance Number : 2331
Certificate Number : R1-CEP 2017-014 - Rev 00
Status : Valid
Issue Date : 2023-04-27
Type : Chemical
Substance Number : 2331
Certificate Number : CEP 2017-253 - Rev 01
Status : Valid
Issue Date : 2023-12-13
Type : Chemical
Substance Number : 2331
Certificate Number : R1-CEP 2016-303 - Rev 00
Status : Valid
Issue Date : 2023-01-16
Type : Chemical
Substance Number : 2331
Certificate Number : R0-CEP 2016-325 - Rev 00
Status : Expired
Issue Date : 2017-08-23
Type : Chemical
Substance Number : 2868
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Dosage Form : Capsule
Grade : Oral
Brand Name : Sodium Stearyl Fumarate G...
Application : Lubricants & Glidants
Excipient Details : Sodium Stearyl Fumarate is used as a lubricant in OSDs to reduce the friction and the adhesion. It also provides tablet strength & disintegration.
Pharmacopoeia Ref : USP, EP, ICH, Q7GMP
Technical Specs : NA
Ingredient(s) : Sodium Stearyl Fumarate
Dosage Form : Cream / Lotion / Ointment
Grade : Topical, Oral
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : Mannitol is used as a filler, bulking agent and taste masking agent in ODT formulations such as tablets.
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Orodispersible Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Disintegrants & Superdisintegrants
Excipient Details : Mannogem 2080 exhibits excellent flow, disintegration and compression properties.
Dosage Form : Orodispersible Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Dosage Form : Tablet
Grade : Oral
Application : Taste Masking
Excipient Details : MS90 is a directly compressible magnesium hydroxide with starch used for chewable tablets due to its smooth mouthfeel and creamy texture.
Pharmacopoeia Ref : NA
Technical Specs : PSD D50: 150-170 µm, Tapped Density: 0.80
Ingredient(s) : Magnesium Hydroxide Excipient
Dosage Form : Tablet
Grade : Oral
Application : Lubricants & Glidants
Excipient Details : Lubristar is used as a lubricant in oral dosage forms such as tablets.
Pharmacopoeia Ref : USP-NF, BP, IP, EP, PSD, DMF, ...
Technical Specs : NA
Ingredient(s) : Sodium Stearyl Fumarate
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Microlose (Lactose Monohydrate & Microcrystalline Cellulose) is used as a diluent in oral dosage forms such as tablets.
Pharmacopoeia Ref : DMF, EXCiPAT, KOSHER, HALAL, W...
Technical Specs : Lactose Monohydrate – 40%, Microcrystalline cellulose – 60%
Ingredient(s) : Lactose Monohydrate
Dosage Form : Tablet
Grade : Oral
Dosage Form : Capsule
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : ProBlend (SMCC) is a co-processed excipient consists of microcrystalline cellulose & colloidal silicon dioxide, used as a diluent & binder in OSDs.
Pharmacopoeia Ref : USP-NF, DMF, EXCiPAT, KOSHER, ...
Technical Specs : NA
Ingredient(s) : Silicified Microcrystalline Cellulose
Dosage Form : Capsule
Grade : Oral
Application : Disintegrants & Superdisintegrants
Excipient Details : Sallyso (Croscarmellose Sodium) is a cross-linked polymer of carboxymethylcellulose sodium, used as a superdisintegrant in tablets and capsules.
Pharmacopoeia Ref : USP-NF, BP, IP, EP, DMF, EXCiP...
Technical Specs : Sallyso 0.5 to 3.0%
Ingredient(s) : Croscarmellose Sodium
Dosage Form : Capsule
Grade : Oral
Application : Disintegrants & Superdisintegrants
Excipient Details : Solvostar (Sodium Starch Glycolate) is used as a superdisintegrant in oral solid dosage forms such as tablets and capsules.
Pharmacopoeia Ref : USP-NF, BP, IP, EP, DMF, EXCiP...
Technical Specs : Solvostar 2% to 8%
Ingredient(s) : Sodium Starch Glycolate
Dosage Form : Tablet
Grade : Oral
Application : Fillers, Diluents & Binders
Excipient Details : Starlose P40 (Starch & Lactose Monohydrate) is used as a diluent in oral dosage forms such as tablets.
Dosage Form : Injectable / Parenteral
Grade : Parenteral
Brand Name : Lactose Monohydrate
Application : Parenteral
Excipient Details : Lactose monohydrate is used as a diluent in inhalation and lyophilized preparations.
Dosage Form : Emulsion
Grade : Parenteral, Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Topical, Oral
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Dosage Form : Injectable / Parenteral
Grade : Parenteral, Oral, Topical
Dosage Form : Emulsion
Grade : Parenteral
Dosage Form : Capsule
Grade : Oral
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
60
PharmaCompass offers a list of Rabeprazole API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Rabeprazole manufacturer or Rabeprazole supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Rabeprazole manufacturer or Rabeprazole supplier.
PharmaCompass also assists you with knowing the Rabeprazole API Price utilized in the formulation of products. Rabeprazole API Price is not always fixed or binding as the Rabeprazole Price is obtained through a variety of data sources. The Rabeprazole Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dexrabeprazole Sodium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dexrabeprazole Sodium, including repackagers and relabelers. The FDA regulates Dexrabeprazole Sodium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dexrabeprazole Sodium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dexrabeprazole Sodium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dexrabeprazole Sodium supplier is an individual or a company that provides Dexrabeprazole Sodium active pharmaceutical ingredient (API) or Dexrabeprazole Sodium finished formulations upon request. The Dexrabeprazole Sodium suppliers may include Dexrabeprazole Sodium API manufacturers, exporters, distributors and traders.
click here to find a list of Dexrabeprazole Sodium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dexrabeprazole Sodium DMF (Drug Master File) is a document detailing the whole manufacturing process of Dexrabeprazole Sodium active pharmaceutical ingredient (API) in detail. Different forms of Dexrabeprazole Sodium DMFs exist exist since differing nations have different regulations, such as Dexrabeprazole Sodium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dexrabeprazole Sodium DMF submitted to regulatory agencies in the US is known as a USDMF. Dexrabeprazole Sodium USDMF includes data on Dexrabeprazole Sodium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dexrabeprazole Sodium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dexrabeprazole Sodium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Dexrabeprazole Sodium Drug Master File in Japan (Dexrabeprazole Sodium JDMF) empowers Dexrabeprazole Sodium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Dexrabeprazole Sodium JDMF during the approval evaluation for pharmaceutical products. At the time of Dexrabeprazole Sodium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Dexrabeprazole Sodium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Dexrabeprazole Sodium Drug Master File in Korea (Dexrabeprazole Sodium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dexrabeprazole Sodium. The MFDS reviews the Dexrabeprazole Sodium KDMF as part of the drug registration process and uses the information provided in the Dexrabeprazole Sodium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Dexrabeprazole Sodium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dexrabeprazole Sodium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Dexrabeprazole Sodium suppliers with KDMF on PharmaCompass.
A Dexrabeprazole Sodium CEP of the European Pharmacopoeia monograph is often referred to as a Dexrabeprazole Sodium Certificate of Suitability (COS). The purpose of a Dexrabeprazole Sodium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dexrabeprazole Sodium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dexrabeprazole Sodium to their clients by showing that a Dexrabeprazole Sodium CEP has been issued for it. The manufacturer submits a Dexrabeprazole Sodium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dexrabeprazole Sodium CEP holder for the record. Additionally, the data presented in the Dexrabeprazole Sodium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dexrabeprazole Sodium DMF.
A Dexrabeprazole Sodium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dexrabeprazole Sodium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dexrabeprazole Sodium suppliers with CEP (COS) on PharmaCompass.
A Dexrabeprazole Sodium written confirmation (Dexrabeprazole Sodium WC) is an official document issued by a regulatory agency to a Dexrabeprazole Sodium manufacturer, verifying that the manufacturing facility of a Dexrabeprazole Sodium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dexrabeprazole Sodium APIs or Dexrabeprazole Sodium finished pharmaceutical products to another nation, regulatory agencies frequently require a Dexrabeprazole Sodium WC (written confirmation) as part of the regulatory process.
click here to find a list of Dexrabeprazole Sodium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dexrabeprazole Sodium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dexrabeprazole Sodium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dexrabeprazole Sodium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dexrabeprazole Sodium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dexrabeprazole Sodium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dexrabeprazole Sodium suppliers with NDC on PharmaCompass.
Dexrabeprazole Sodium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dexrabeprazole Sodium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dexrabeprazole Sodium GMP manufacturer or Dexrabeprazole Sodium GMP API supplier for your needs.
A Dexrabeprazole Sodium CoA (Certificate of Analysis) is a formal document that attests to Dexrabeprazole Sodium's compliance with Dexrabeprazole Sodium specifications and serves as a tool for batch-level quality control.
Dexrabeprazole Sodium CoA mostly includes findings from lab analyses of a specific batch. For each Dexrabeprazole Sodium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dexrabeprazole Sodium may be tested according to a variety of international standards, such as European Pharmacopoeia (Dexrabeprazole Sodium EP), Dexrabeprazole Sodium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dexrabeprazole Sodium USP).